Related references
Note: Only part of the references are listed.Cyclooxygenase-2 (Cox-2) and blast cells of patients with acute leukemia
Christelle Vincent et al.
LEUKEMIA RESEARCH (2008)
Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: Role of COX-2 and MDR-1
Kalle M. Arunasree et al.
LEUKEMIA RESEARCH (2008)
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
Markus Jensen et al.
INVESTIGATIONAL NEW DRUGS (2008)
Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells
Elizabeth P. Ryan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating Hematologic malignancies including myeloma
Suzanne Lentzsch et al.
ARCHIV DER PHARMAZIE (2007)
Treatment of multiple myeloma with SDX-308
Rentian Feng et al.
DRUG NEWS & PERSPECTIVES (2007)
Regular analgesic use and risk of multiple myeloma
Kirsten B. Moysich et al.
LEUKEMIA RESEARCH (2007)
Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of β-catenin/TCF pathway
H. Yasui et al.
LEUKEMIA (2007)
SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-κB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth
Rentian Feng et al.
BLOOD (2007)
Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction
Sung-Keum Seo et al.
APOPTOSIS (2007)
Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: From lab to clinic
D. J. A. de Groot et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells
Elin Lindhagen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells
Pawel Robak et al.
LEUKEMIA & LYMPHOMA (2006)
Use of nonsteroidal antinflammatory drugs and non-Hodgkin lymphoma: A population-based case-control study
E. Dawn Flick et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2006)
Does low-dose aspirin have antineoplastic effects in multiple myeloma?
Rachid Baz et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells
Paola Neri et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Cyclooxygenase isozymes are expressed in human myeloma cells but not involved in anti-proliferative effect of cyclooxygenase inhibitors
J Ding et al.
MOLECULAR CARCINOGENESIS (2006)
Opposing effects of aspirin and acetaminophen use on risk of adult acute leukemia
JR Weiss et al.
LEUKEMIA RESEARCH (2006)
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics
CM Ulrich et al.
NATURE REVIEWS CANCER (2006)
Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells
S Nakamura et al.
LEUKEMIA RESEARCH (2006)
Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2
S Fries et al.
GASTROENTEROLOGY (2006)
Anti-inflammatory effects of indomethacin's methyl ester derivative and induction of apoptosis in HL-60 cells
SH Chao et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2005)
Medication use and risk of non-Hodgkin's lymphoma
ET Chang et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2005)
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma
H Yasui et al.
BLOOD (2005)
The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome
A Czibere et al.
CELL CYCLE (2005)
Prescription drug use and risk of acute myeloid leukemia by French-American-British subtype: Results from a Los Angeles County case-control study
JM Pogoda et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma
JA Baker et al.
CANCER CAUSES & CONTROL (2005)
The R-enantiomer of the nonsteroidal anti inflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis
SK Kolluri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Cyclooxygenase-2: How good is it as a target for cancer chemoprevention?
MA Hull
EUROPEAN JOURNAL OF CANCER (2005)
Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells
U Puhlmann et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Phosphorylation status of c-Kit and Epo receptors, and the presence of wild-type p53 confer in vitro resistance of murine erythroleukemic cells to Celecoxib
D Cervi et al.
ONCOGENE (2004)
Activation of the Wnt signaling pathway in chronic lymphocytic leukemia
DS Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study
ET Chang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Cyclooxygenase-1, but not-2, is upregulated in NB4 leukemic cells and human primary promyelocytic blasts during differentiation
B Rocca et al.
LEUKEMIA (2004)
Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in connecticut United States women
YW Zhang et al.
CANCER CAUSES & CONTROL (2004)
Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma
JR Cerhan et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus-negative participants in San Francisco
EA Holly et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2003)
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs
G Reid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy
P Ricchi et al.
BRITISH JOURNAL OF CANCER (2003)
Prescription medications associated with a decreased risk of non-Hodgkin's lymphoma
AB Beiderbeck et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2003)
Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin's lymphoma (NHL) (United States)
I Kato et al.
CANCER CAUSES & CONTROL (2002)
Enhanced clearance of leukemic lymphocytes in B-cell chronic lymphocytic leukemia with etodolac
FA Nardella et al.
BLOOD (2002)
Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues
MJ Thun et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer
AJ Dannenberg et al.
LANCET ONCOLOGY (2001)
Inhibitors of cyclooxygenase-2 (COX-2) suppressed the proliferation and differentiation of human leukaemia cell lines
Y Nakanishi et al.
EUROPEAN JOURNAL OF CANCER (2001)
15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells
I Shureiqi et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2
AL Hsu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Medical history and risk of Hodgkin's and non-Hodgkin's lymphomas
A Tavani et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2000)
The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action
ML Smith et al.
EUROPEAN JOURNAL OF CANCER (2000)
Share Paper
